Henry Ford Hospital Medical Journal
Volume 23 | Number 4

Article 6

12-1975

Immunologic Assessment in Patients with Prostatic
Carcinoma
Richard C. Klugo

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health
Commons
Recommended Citation
Klugo, Richard C. (1975) "Immunologic Assessment in Patients with Prostatic Carcinoma," Henry Ford Hospital Medical Journal : Vol.
23 : No. 4 , 179-182.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol23/iss4/6

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry
Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons.

H e n r y Ford Hosp. M e d . Journal
V o l . 2 3 , N o . 4 , 1 9 7 5 — S y m p o s i u m , Prostate C a r c i n o m a

Immunologic Assessment in Patients
with Prostatic Carcinoma
Richard C. Klugo, M D *

Immunologic evaluation of patients with
urologic carcinoma has been used to obtain
a correlation between immune responsiveness and tumor progression.^"' This information could lead to improved management
of these patients by avoiding or limiting
therapy which might depress immune response." Alternately or additionally, a nonspecific or tumor-specific antigen might
enhance the immune response to limit tumor
extension.^''

The role of immune mechanisms in the
development and control of prostatic carcinoma appears to be complicated by the
endocrine response of some tumors. The
progression of endocrine-independent
tumors is more directly related to host-immune
response. Evaluation of the role of chemotherapeutic agents must include their effect
on the host-immune response. The use of
BCC in patients with metastatic prostatic
carcinoma produces no alteration in cellmediated immunity but produces
local
tumor necrosis. The use of nonspecific antigens to enhance host-immune response may
be more effective when used as adjuvant
therapy in earlier stages of
prostatic
adenocarcinoma.

The presence or absence of cell-mediated
immunocompetence correlates very closely
to the disease stage in bladder c a r c i noma.^''-^ Preliminary studies of i m m u nocompetence in patients with carcinoma of
the prostate are conflicting.''" Catalona and
associates found no correlation between
lack of immunocompetenceand tumor stage
with carcinoma of the prostate.' Huus and
Perskey, alternatively, found a direct correlation between D N C B reactivity and
tumor stage.' They suggested that a careful
evaluation of tumor stage is important to the
proper assessment of reactivity with carcinoma of the prostate. However, when the
patients receiving endocrine therapy are
eliminated from Catalona's series, tumor
progression correlates very closely with immune response. It must be noted that the
exact role of host-immune response with
carcinoma of the prostate may be altered
w h e n h o r m o n e dependent tumors are
present.
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The cell-mediated response in carcinoma
of the prostate is altered by what appears to
be two different mechanisms. Serum factors
have been shown to produce an impaired
l y m p h o c y t i c reactivity to p h y t o h e m a g glutinin (PHA)."'^"'"'^''^" This may be the
resultof a blocking antibody, probably present in the A2 globulin fraction. A second
mechanism appears to involve a decrease in
the absolute lymphocyte count as well as
abil ity of these lymphocytes to react to PHA
when incubated with normal serum.''
Alteration of immune response may play a
significant role in the progression of prostatic
carcinoma. Present modes of therapy have
shown they may alter lymphocyte response
and total lymphocytic counts. The ultimate
role of these responses is not yet fully apparent but is the subject of further investigation.

Radiation therapy
Patients in all stages of prostatic carcinoma, who had a course of radiation
therapy within 12 months of lymphocyte
counts, showed significant depression of
total and T lymphocyte counts.^' This reduction was greater in patients with metastatic
disease. It would appear that recovery of
lymphocyte counts requires a minimum of
24 months.^'' During this period of immune
suppression, metastatic disease may escape
immune controls. It would seem logical
during this time to attempt to enhance immune response or to use adjuvant chemotherapy or endocrine therapy.

Chemotherapy
Agents with antiproliferative properties
against lymphocytes are being used more
and it is well to recognize their effect in the
total management of prostatic carcinoma.
Cyclophosphamide produces a profound
leukopenia within 7 to 12 days. It also has the
potential to induce specific tolerance when
administered during the inductive phase of
immune response. Mounting evidence sug-

gests that cyclophosphamide has a preferential effect on B lymphocytes. Thus, the
reduction of e n h a n c i n g antibodies by B
lymphocyte suppression may increase cellular tumor cytotoxic activity."

5-Fluoruracil
This agent exerts its antineoplastic effect
during the S phase of the cell cycle. In
therapeutic doses it suppresses delayed hypersensitivity and antibody production. It
would appear that immunosuppression with
this drug might allow tumor escape and
progression. The depression of lymphocyte
levels with this agent is reflected in a moderate T lymphocyte reduction. The most interesting observation is with 5-FU-induced
tumor remission where T lymphocyte counts
rebounded to above pretreatment levels."'"
This may be explained by a reduction of
tumor bulk and, therefore, serum factors
which may suppress lymphocyte proliferation. To evaluate properly the antineoplastic
agent's capabil ities to control tumor growth,
it is apparent that concurrent host immune
monitoring is essential.

Estrogen therapy
(Diethyl Stilbesterol 1 mg/d
Chlorotrianisene
12 mg/d)
In patients treated with these estrogens
p h y t o h e m a g g l u t i n in-stimulated blastogenesis was depressed. Despite this finding,
there was an elevation in the absolute
lymphocyte and monocyte counts as well as
i m p r o v e d delayed cutaneous hypersensitivity response to PPD. Examination of
humoral immune parameters showed an
increase in the total protein most evident in
the Alpha 2 globulin.
Caution must be exerted in interpreting
the host-immune response during estrogen
therapy, particularly if significant tumor volume reduction occurs during this time. It
would seem that, if the total immune response is depressed duringestrogen therapy,
an approach to combined therapy with im-
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mune s t i m u l a t i o n or pulse
therapy should be considered.

endocrine

limited. The modes of administration have
been oral as well as intralesional. Oral BCG
failed to produce any improvement in cellular immune response or tumor regression.

Studies, in a small group of patients, of
lymphocyte populations pre- and postorchiectomy produced inconclusive evidence. Improved absolute l y m p h o c y t e
counts were reported in 3 of 5 patients.
However, indications of tumor volume alterations were not n o t e d . " It would seem
that considerable study should be directed to
Investigation of host-immune response preand post-ore hiectomy.

Intralesional injection produces localized
t u m o r necrosis but fails to induce any
change in cellular immune response.''^^
Side effects of intralesional injections occurred with the third and fourth injections
and consisted of fever. Anaphylactic reaction has been reported with intralesional
injection. The poor response to BCG in
patients with advanced prostatic cancer may
indicate a need for other modes of therapy
to reduce t u m o r bulk prior to i m m u notherapy. The need for evaluation of other
antigens (corynibacterium parvum, KLH)"
and other sites of introduction (bladder,
lower extremity) appears indicated in future
attempts to enhance the immune response.

Orchiectomy

BCG-Bacillus Calmette Guerin
This antigen has been used to produce
some dramatic responses with melanomas.^"
Its use with prostatic carcinoma has been
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